drugset / Trial / NCT01271790
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
Timeline
- Start
- 2010-10
- Primary completion
- 2013-01
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tegobuvir | Small molecule | 30 mg | Oral |
| Comparator | vedroprevir | Small molecule | 200 mg | Oral |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Other |
| Comparator | Ribavirin | Small molecule | 500 mg | Oral |
| Comparator | Ribavirin | Small molecule | 600 mg | Oral |